Showing 21-30 of 33 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Development of a safe and effective islet-targeted nanoplasmid based CXCL12 gene delivery system using cationic nanobubble-mediated sonotransfection to restore and immune protect the residual beta cell mass in T1D | Massachusetts General Hospital | Mark Poznansky | Cures | 01-April-2023 to 31-March-2027 | $777.168,00 |
| Epithelial Immune Sentinels in T1D Autoimmune Kidney Disease | Massachusetts General Hospital | Maria Agustina Battistone | Improving Lives | 01-September-2026 to 31-August-2028 | $189.099,97 |
| Understanding common tissue tolerance mechanisms in autoimmunity | Massachusetts General Hospital | Gary Reynolds | Cures | 01-September-2025 to 28-February-2027 | $150.000,00 |
| The T1D Parent Check-In: A Preventative Intervention | Massachusetts General Hospital | Ellen O’Donnell | Improving Lives | 01-July-2023 to 01-September-2026 | $390.792,17 |
| A Nanosensor Embedded Device for Rapid Insulin Measurement | Massachusetts Institute of Technology | Michael Strano | Improving Lives | 01-April-2024 to 31-March-2027 | $698.927,98 |
| Assessing use of primary and secondary CVD prevention therapies in people with T1D and developing strategies to increase uptake | Putnam Associates | Thomas Marder | Improving Lives | 01-August-2026 to 31-July-2027 | $615.000,00 |
| Implementing Best Practice Advisories to Reduce Inequities in Technology Use for people with Type 1 Diabetes | T1D Exchange, Inc. | Nicole Rioles | Improving Lives | 01-May-2024 to 30-April-2027 | $1.995.534,06 |
| Expanding Access to T1D Care through the PEN-Plus Strategy | The Brigham and Women’s Hospital, Inc. | Gene Bukhman | Mission | 01-August-2024 to 31-July-2027 | $5.999.961,29 |
| A prodrug system for targeted activation of small molecules in beta cells | The Brigham and Women’s Hospital, Inc. | Amit Choudhary | Cures | 01-February-2024 to 31-January-2027 | $2.250.000,00 |
| Artificial Intelligence-driven redesign of beta cell regulatory logic for resilience to inflammation | University of Massachusetts Medical School | Rene Maehr | Cures | 01-April-2026 to 31-March-2027 | $199.999,88 |